A vitamin sold at any pharmacy counter is now part of a real medical study against one of the deadliest cancers known to medicine, and the early numbers are turning heads in brain tumor research.
Quick Take
- University of Calgary researchers added high-dose, controlled-release niacin, a form of vitamin B3, to standard glioblastoma treatment.
- Early results from 24 patients showed 82% had no cancer progression after six months.
- That is a 28% jump over historical benchmarks for this aggressive brain cancer.
- A peer-reviewed study backs up the finding, and researchers think niacin may boost the immune system’s fight against tumors.
A Common Vitamin Enters the Fight Against Brain Cancer
Glioblastoma kills fast. It is the most aggressive form of brain cancer, and most patients do not survive long after diagnosis. Standard treatment combines surgery, radiation, and chemotherapy, but results have barely improved in years. That grim backdrop is why a clinical trial out of the University of Calgary has caught so much attention: it tests whether a common vitamin can change the odds.
How The Niacin Trial Works
The trial, registered as NCT04677049, adds controlled-release niacin to the usual chemoradiation plan for newly diagnosed glioblastoma patients. Researchers at the Tom Baker Cancer Centre designed it in two phases. Phase one raised the niacin dose step by step to find the highest amount patients could safely tolerate. That maximum turned out to be 2000 milligrams a day.
Phase two then measures whether that dose, paired with standard treatment, actually slows the cancer down. Researchers set a clear bar before starting: if six-month progression-free survival did not beat historical results by at least 20%, they would stop the trial.
The Early Numbers Beat Expectations
Early results blew past that bar. Among the first 24 patients, 82% showed no sign of cancer progression at six months. Researchers describe that as a 28% absolute increase compared to prior studies of standard treatment alone. A peer-reviewed analysis published in the Journal of Neuro-Oncology confirmed the same number through independent radiology review, lending real scientific weight beyond a university press release.
Named researchers, including Voon Wee Yong and Gloria Roldan Urgoiti at the Hotchkiss Brain Institute and Arnie Charbonneau Cancer Institute, lead the effort. That matters. This is not an anonymous internet health claim. It is an identifiable team running a registered clinical trial at a respected Canadian cancer center, publishing results researchers elsewhere can scrutinize and build on.
Why Niacin Might Help: The Immune System Angle
Scientists think niacin may work by waking up the immune system’s attack on tumor cells. A separate first-in-human study tied to the same trial found that niacin treatment increased memory T cells and natural killer cells in patients’ blood, while lowering certain monocytes linked to suppressing immune response. Those are the kinds of cells the body uses to hunt down and destroy cancer, giving researchers a plausible explanation for why the tumors might be held back.
Flushing, a warm, reddish skin reaction, showed up as the main side effect, but researchers say it eased over time when doses increased gradually. That is a familiar nuisance to anyone who has taken niacin supplements before, and it appears manageable within a supervised clinical setting rather than a dealbreaker for patients.
What Still Needs to Be Proven
These results come from just 24 patients, an early and small sample. A full phase two readout, including overall survival data and a broader patient group, will offer a clearer verdict down the road. Still, for a disease that has resisted real progress for decades, an inexpensive vitamin showing this kind of signal, backed by named researchers and a peer-reviewed journal, deserves serious attention rather than dismissal.
High-dose vitamin B3 is showing intriguing early promise as an addition to standard glioblastoma treatment, with 82% of patients in a small trial remaining progression-free after six months. Researchers believe niacin may help revive immune cells suppressehttps://t.co/iyebzQpvQo
— Michael W. Deem (@Michael_W_Deem) October 4, 2026
Glioblastoma patients and their families have waited a long time for genuinely hopeful news. This trial does not promise a cure, but it does offer something rare in brain cancer research: a cheap, accessible compound producing numbers worth watching closely as more data rolls in.
Sources:
sciencedaily.com, ucalgary.ca, brainlife.org, cumming.ucalgary.ca, can-acn.org, foxnews.com
